Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458943 | 0.71 | ATM (0.58) | PTK2PBRM1ATM | |
| SCHEMBL30277848 | 0.70 | ATM (0.56) | HCAR2PTK2PBRM1KDM4EATM | |
| SCHEMBL2174213 | 0.70 | ATM (0.56) | HCAR2PTK2PBRM1KDM4EATM | |
| SCHEMBL14753984 | 0.70 | CCR1 (0.54) | HCAR2GAAKDM4E | |
| SCHEMBL20265528 | 0.70 | PTK2 (0.50) | HCAR2PTK2PBRM1GAAATM | |
| SCHEMBL17678907 | 0.70 | PTK2 (0.54) | HCAR2PTK2PBRM1ATM | |
| SCHEMBL14840715 | 0.69 | EPHX2 (0.34) | — | |
| SCHEMBL16583618 | 0.68 | ATM (0.53) | HCAR2PTK2GAAATM | |
| SCHEMBL30907323 | 0.68 | HAO1 (0.39) | — | |
| SCHEMBL14116389 | 0.66 | PTK2 (0.49) | HCAR2PTK2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050341-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050341-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | RYR2, CACNA1E, RYR1 | HCAR2 95/4885PTK2 2387/4885PBRM1 1580/4885 |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | ORAI1, CACNA1E, RYR2 | HCAR2 107/4885PTK2 2451/4885PBRM1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.